ESMO 2018 | Is CAR T-cell therapy for solid malignancies?
Michel Sadelain
CAR T-cell therapy has good prospects for moving into the field of solid tumors, suggests Michel Sadelain, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. With adjustments, particularly for the tumor microenvironments, Dr Sadelain believes it will be possible to use CAR-T technology in the solid setting.
Related videos
1:26 Comparison of investigator-initiated and industry-initiated trials by Dr Sridhar
Srikala Sridhar
2:46 Radiology advancements and the management of genitourinary cancers
Julia Fielding
1:33 Radiomics updates: data science in radiology
Julia Fielding
1:55 Radiotherapy: the need for further research
Nicolas Magne
2:13 Updates in HR-Positive mBCa
Erika Hamilton
